Barclays’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-49,787
| Closed | -$1.22M | – | 7599 |
|
|
2017
Q4 | $1.22M | Buy |
49,787
+49,372
| +11,897% | +$949K | ﹤0.01% | 2917 |
|
|
2017
Q3 | $7K | Buy |
415
+406
| +4,511% | +$7.03K | ﹤0.01% | 6320 |
|
|
2017
Q2 | $0 | Sell |
9
-1,580
| -99% | -$22K | ﹤0.01% | 7170 |
|
|
2017
Q1 | $22K | Buy |
1,589
+1,272
| +401% | +$20.4K | ﹤0.01% | 5776 |
|
|
2016
Q4 | $7K | Sell |
317
-1,521
| -83% | -$29.2K | ﹤0.01% | 6055 |
|
|
2016
Q3 | $41K | Buy |
+1,838
| New | +$34.5K | ﹤0.01% | 5095 |
|
|
2016
Q2 | – | Sell |
-700
| Closed | -$13K | – | 6855 |
|
|
2016
Q1 | $13K | Buy |
+700
| New | +$11.3K | ﹤0.01% | 5403 |
|
|
2015
Q4 | – | Sell |
-28
| Closed | -$1K | – | 6977 |
|
|
2015
Q3 | $1K | Sell |
28
-1,275
| -98% | -$28.4K | ﹤0.01% | 6724 |
|
|
2015
Q2 | $33K | Buy |
1,303
+1,234
| +1,788% | +$31.2K | ﹤0.01% | 5409 |
|
|
2015
Q1 | $1K | Buy |
+69
| New | +$1.49K | ﹤0.01% | 7016 |
|
Barclays's ENTL Position: Q1 2018 in Review
Barclays sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q1 2018, closing a stake of 49,787 shares — an estimated $1.22M sold.
Barclays first reported a position in ENTL in Q1 2015 and held it in 10 quarters. The position peaked at $1.22M in Q4 2017. 0 funds tracked by Wall St. Rank hold ENTL as of Q1 2018.
- Barclays reported no remaining Entellus Medical, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
- Barclays sold 49,787 Entellus Medical, Inc. Common Stock shares in Q1 2018, an estimated $1.22M.
- Barclays first reported a position in Entellus Medical, Inc. Common Stock in Q1 2015 and held it in 10 quarters.
- Barclays's Entellus Medical, Inc. Common Stock position peaked at $1.22M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q1 2018.
Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.